The POLE subtype of Endometrial carcinoma (EC) is linked to a favourable prognosis in the molecular classification. We proposed to ascertain the potential connection between the POLE subtype and improved prognosis. In order to forecast the prognosis, least absolute shrinkage and selection operator (LASSO) Cox regression analysis and weighted gene co-expression network analysis (WGCNA) were employed, and a POLE-related risk signature (PRS) model was developed and validated. Single-sample gene set enrichment analysis (ssGSEA) with the "GSVA" package was employed to analyse immunity characteristics. Drug susceptibility studies were conducted to compare the half-maximal inhibitory concentration (IC50) of medicines between high- and low-risk groups. The PRS model was generated employing the LASSO Cox regression coefficients of the ELF1, MMADHC, andAL021707.6 genes. Our study demonstrated that the risk score was linked to tumour stage, grade, and survival. Furthermore, the low-risk group possessed elevated levels of gene expression connected with immunological checkpoints and HLA. Our outcomes emerged that the PRS model might have value in identifying patients with a good prognosis and in facilitating personalised treatment in the clinic.
Keywords: A POLE-Related risk score signature (PRS); Drug sensitivity; Endometrial carcinoma; Immunity; Prognosis.
© 2024 The Authors.